Radionetics Oncology
Menlo Park, US · Founded 2021 · Delaware corporation · 4 known investors
Find your way into Radionetics Oncology
304 people in our graph share verified history with the Radionetics Oncology team — schools, employers, funds. One of them is your warm intro.
Frank Zhouunlockedknows Umesh Gangadharmath · together at University of California Los Angeles (overlapped)
knows the team · via Villanova University
knows the team · via Merrimack Pharmaceuticals
×2knows the team · via University of California Los Angeles
knows the team · via Radionetics
×5knows the team · via Bayer HealthCare
Founders & leadership
BE
Brett EwaldinExecutiveBrett Ewald has spent 20 years developing oncology therapeutics across pharma, biotech, and academia, with expertise in radiopharmaceuticals, small molecules, monoclonal antibodies, and immunotherapies. He was a founding employee at a clinical-stage radiopharmaceutical company and served as interim CEO during a financing and strategic planning period.
UG
Umesh GangadharmathinExecutiveUmesh Gangadharmath is a radiopharmaceutical scientist with more than 19 years of experience in radiopharmaceutical development and GMP manufacturing. His background includes serving as Assistant Professor and Biomedical Cyclotron Facility Director at UCLA, Senior Scientist in Radiochemistry at Siemens Molecular Imaging, and founding member of Optimal Tracers (a radiopharmaceutical CDMO acquired by Telix Pharmaceuticals), and he currently serves as Chief Technical Officer at Radionetics Oncology.
IM
Istvan MolnarinExecutiveIstvan Molnar MD is a hematologist-oncologist who trained in internal medicine and hematology-oncology in the United States and previously worked as an Assistant Professor at Wake Forest University before spending two decades in pharmaceutical development at Bayer, Merrimack, Fusion Pharmaceuticals, and Lantheus Medical Imaging, where he held roles ranging from medical affairs to chief medical officer and contributed to regulatory approvals for multiple oncology and imaging drugs.
YZ
Yunfei ZhuExecutive
AK
Ana KusnetzowinExecutive
SS
Scott StruthersNamed on SEC filing
Board
Investors · 4
Reported raises · per SEC filings
Form D private placements$54.2M disclosed across 1 round · 2023
▶$54.2MraisedAug 2023 · 6 investors · PharmaceuticalsRule 506(b)
▶$54.2MraisedAug 2023 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Brett EwaldExecutive Officer
- Andrew SchwabDirector
- Umesh GangadharmathExecutive Officer
- Dan EstesExecutive Officer, Director
- Istvan MolnarExecutive Officer
- Yunfei ZhuExecutive Officer
- Ana KusnetzowExecutive Officer
- Scott StruthersDirector
- Offering amount
- $68.7M
- Amount sold
- $54.2M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Radionetics Oncology's investors?
- Radionetics Oncology's investors include DCVC (Data Collective), Frazier Life Sciences, 5AM Ventures, DCVC Bio.
- How much funding has Radionetics Oncology raised?
- Radionetics Oncology has disclosed $54.2M raised across 1 round.
- Where is Radionetics Oncology headquartered?
- Radionetics Oncology is headquartered in Menlo Park, US.